MetrINo: Metrology for innovative nanomedicine
The following project is part of our research in the field of X-ray flourescence.
Project description
MetrINo responds to the immediate metrological need of industry, regulatory authorities and policy makers for the development and validation of traceable measurement methods and reference materials for the assessment of the critical quality characteristics of nanotherapeutics. The project focuses on clinical formulations, including synthetic lipid-based nanoparticles and metal oxide nanoparticles used for local cancer treatment, gene therapy, vaccines (COVID-19) or as contrast agents. Reference materials will be developed and used for measurement control. MetrINo will develop and validate traceable methods for measuring the physical properties of nanoparticles, their biotransformation in biological media, and methods for their identification and quantification in cells and tissues.
The project is coordinated by the LNE, Laboratoire national de métrologie et d'essais. The international consortium, involving 10 countries, consists of 10 national metrology institutes or designated institutes (LNE, BAM, PTB, RISE, SMD, TUBITAK, INRIM, LGC, NPL, NRC), the ETPN Nanomedicine association; 3 research and technology organisations (SINTEF, EMPA, CEA), 3 academic partners (UPv, OVGU, UGent), 1 hospital (OGSA), 2 pharmaceutical companies (NanoPET, NanoBiotix) and 1 SME (Curadigm), which are key experts in the field of nanomedicine. MetrINo is also supported by more than 20 international stakeholders.
more information on the Metrino homepage
The project is funded in the period 7/2023-06/2026 by EURAMET (European Association of National Metrology Institutes).
